SDO, UKM to start trial for fatty liver disease treatment

PETALING JAYA: Sime Darby Oils (SDO), the downstream unit of Sime Darby Plantation Bhd announced a collaboration via a memorandum of agreement with Universiti Kebangsaan Malaysia (UKM) to begin the world’s first clinical trial to determine tocotrienols which is derived from palm oil could be used as a therapeutic approach for the treatment of non-alcoholic fatty liver disease (NAFLD).

“This is potentially a very exciting development for us which if the results are favorable could lead to tocotrienols being prescribed as a medicine for NAFLD, ” SDO’s managing director, Mohd Haris Mohd Arshad said at a press conference after the announcement yesterday.

Limited time offer:
Just RM5 per month.

Monthly Plan


Billed as RM5/month for the 1st 6 months then RM13.90 thereafters.

Annual Plan


Billed as RM148.00/year

1 month

Free Trial

For new subscribers only

Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

CNH picks Iveco Group’s Marx as new CEO
Blackstone makes new offer to buy Hipgnosis
Factors influencing Vietnam’s FMCG trade
Ecoceres’ local unit forecast to start in 2H25
Conference on how AI will elevate marketing
US clean tech withers as imports are blocked
Cooling equipment industry heating up
Tesla spends weekend cutting prices of cars
Beijing is at the front and centre of gold’s record-breaking rally
VN-Index technical recovery hits speed bump

Others Also Read